Bryan Oronsky

5.1k total citations · 2 hit papers
147 papers, 3.6k citations indexed

About

Bryan Oronsky is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Bryan Oronsky has authored 147 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Oncology, 55 papers in Molecular Biology and 29 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Bryan Oronsky's work include Lung Cancer Research Studies (23 papers), Cancer, Hypoxia, and Metabolism (20 papers) and Epigenetics and DNA Methylation (17 papers). Bryan Oronsky is often cited by papers focused on Lung Cancer Research Studies (23 papers), Cancer, Hypoxia, and Metabolism (20 papers) and Epigenetics and DNA Methylation (17 papers). Bryan Oronsky collaborates with scholars based in United States, South Africa and Finland. Bryan Oronsky's co-authors include Corey A. Carter, Susan J. Knox, Arnold L. Oronsky, Tony R. Reid, Tony Reid, Jan Scicinski, Scott Caroen, Daniel Morgensztern, C. Patrick and Jan Scicinski and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Bryan Oronsky

146 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas

2017 437 citations Bryan Oronsky, Corey A. Carter et al. Neoplasia profile →
A Review of Persistent Post-COVID Syndrome (PPCS)

2021 269 citations Bryan Oronsky, Christopher Larson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bryan Oronsky United States	30	1.4k	1.3k	658	517	509	147	3.6k
Glenn J. Lesser United States	35	1.2k 0.8×	1.7k 1.4×	388 0.6×	1.3k 2.4×	378 0.7×	211	5.2k
Sui Zhang United States	26	1.3k 1.0×	1.5k 1.2×	391 0.6×	439 0.8×	210 0.4×	91	3.9k
Therese A. Dolecek United States	25	648 0.5×	1.0k 0.8×	690 1.0×	789 1.5×	233 0.5×	45	4.8k
Yahiya Y. Syed New Zealand	36	1.0k 0.7×	1.3k 1.0×	397 0.6×	519 1.0×	420 0.8×	107	3.8k
Balázs Döme Hungary	44	2.1k 1.5×	2.6k 2.1×	466 0.7×	1.4k 2.7×	601 1.2×	199	5.7k
Francesco Torino Italy	25	1.4k 1.0×	985 0.8×	392 0.6×	439 0.8×	263 0.5×	95	3.0k
Qin Li China	31	1.3k 1.0×	1.1k 0.9×	205 0.3×	1.2k 2.3×	406 0.8×	154	3.9k
Yulin Liu China	28	882 0.6×	1.4k 1.1×	268 0.4×	538 1.0×	279 0.5×	180	3.3k
Timothy W. Synold United States	39	2.3k 1.6×	2.4k 1.9×	246 0.4×	651 1.3×	286 0.6×	194	5.9k
Cody J. Peer United States	33	1.5k 1.1×	1.8k 1.4×	204 0.3×	559 1.1×	626 1.2×	156	4.0k

Countries citing papers authored by Bryan Oronsky

Since Specialization

Citations

This map shows the geographic impact of Bryan Oronsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan Oronsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan Oronsky more than expected).

Fields of papers citing papers by Bryan Oronsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan Oronsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan Oronsky. The network helps show where Bryan Oronsky may publish in the future.

Co-authorship network of co-authors of Bryan Oronsky

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan Oronsky. A scholar is included among the top collaborators of Bryan Oronsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan Oronsky. Bryan Oronsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reid, Tony, Christopher Larson, Bryan Oronsky, et al.. (2024). CAR expression in invasive breast carcinoma and its effect on adenovirus transduction efficiency. Breast Cancer Research. 26(1). 131–131. 1 indexed citations

Bonomi, Marcelo, David J. Sher, Rafi Kabarriti, et al.. (2024). RRx-001 Affects Multiple Toxicities in Patients Receiving Concomitant Chemoradiation for Head and Neck Cancers: Observations of the PREVLAR Phase II Trial. 1 indexed citations

Reid, Tony, Bryan Oronsky, Scott Caroen, et al.. (2023). Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME). Frontiers in Immunology. 14. 1104753–1104753. 14 indexed citations

Oronsky, Bryan, Lori H. Takahashi, Richard D. Gordon, et al.. (2023). RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist. Frontiers in Oncology. 13. 1204143–1204143. 14 indexed citations

Oronsky, Bryan. (2023). Profile EpicentRx, Inc. Human Vaccines & Immunotherapeutics. 19(1). 2184963–2184963. 2 indexed citations

Larson, Christopher, Omonigho Aisagbonhi, Sarah L. Blair, et al.. (2023). A Local and Abscopal Effect Observed with Liposomal Encapsulation of Intratumorally Injected Oncolytic Adenoviral Therapy. Cancers. 15(12). 3157–3157. 6 indexed citations

Kesari, Santosh, et al.. (2023). Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient. SHILAP Revista de lepidopterología. 16(1). 178–182. 4 indexed citations

Oronsky, Bryan, et al.. (2023). Data Management 101 for drug developers: A peek behind the curtain. Clinical and Translational Science. 16(9). 1497–1509. 1 indexed citations

Oronsky, Bryan, et al.. (2022). RRx-001 and the “Right stuff”: Protection and treatment in outer space. Life Sciences in Space Research. 35. 69–75. 10 indexed citations

10.

Sher, David J., Marcelo Bonomi, Dukagjin Blakaj, et al.. (2020). Results of a Randomized, Open Label, Multicenter Trial Assessing the Safety, Dose and Schedule of RRx-001 (R001) in Reducing Severe Oral Mucositis (SOM) in Patients Receiving Chemoradiation (CRT) for Oral Cavity/oropharynx Squamous Cell Carcinoma (OSCC). International Journal of Radiation Oncology*Biology*Physics. 108(3). S107–S108. 3 indexed citations

11.

Oronsky, Bryan, Tony R. Reid, Christopher Larson, et al.. (2019). REPLATINUM Phase III Randomized Study: RRx-001 + Platinum Doublet Versus Platinum Doublet in Third-Line Small Cell Lung Cancer. Future Oncology. 15(30). 3427–3433. 47 indexed citations

12.

Oronsky, Bryan, Curtis L. Scribner, Rahul Aggarwal, & Pedro Cabrales. (2019). RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition. Journal of Cancer Research and Clinical Oncology. 145(8). 2045–2050. 12 indexed citations

13.

Oronsky, Bryan, Tony R. Reid, Arnold L. Oronsky, & Corey A. Carter. (2017). What's New in SCLC? A Review. Neoplasia. 19(10). 842–847. 137 indexed citations

14.

Oronsky, Bryan, Jan Scicinski, & Pedro Cabrales. (2016). Abstract 12627: Clinical Anticancer Agent, RRx-001, protects From Doxorubicin-Induced Cardiotoxicity. Circulation. 134(suppl_1). 1 indexed citations

15.

Carter, Corey A., Bryan Oronsky, Scott Caroen, et al.. (2016). Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets. Case Reports in Oncology. 9(2). 285–289. 8 indexed citations

16.

Carter, Corey A., Paul Peterson, Mary Quinn, et al.. (2016). Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Reports in Oncology. 9(1). 164–170. 12 indexed citations

17.

Carter, Corey A., Bryan Oronsky, Jan Scicinski, et al.. (2015). Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor. Case Reports in Oncology. 8(3). 461–465. 11 indexed citations

18.

Oronsky, Bryan, Gary R. Fanger, Neil Oronsky, Susan J. Knox, & Jan Scicinski. (2014). The Implications of Hyponitroxia in Cancer. Translational Oncology. 7(2). 167–173. 23 indexed citations

19.

Oronsky, Bryan, Tony Reid, Susan J. Knox, & Jan Scicinski. (2012). The Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents. Translational Oncology. 5(4). 226–229. 35 indexed citations

20.

Oronsky, Bryan, Susan J. Knox, & Jan Scicinski. (2011). Six Degrees of Separation: The Oxygen Effect in the Development of Radiosensitizers. Translational Oncology. 4(4). 189–198. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact